Arthur Klausner, MBA
Partner
Arthur joined Pappas in 2005 as a Partner. From 1990-2004, he was with Domain Associates, a venture capital firm specializing in life sciences companies, serving as a General Partner from 1997 until 2004. Prior to becoming a venture capitalist, Arthur spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. He has previously been a board member at Santarus (IPO in 2004, Nasdaq: SNTS), X-Ceptor (acquired by Exelixis in 2004), and Altea Therapeutics, and he was a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and Cerexa (acquired by Forest Laboratories in 2007). Arthur is currently on the board of CeNeRx BioPharma, Gentis, and Syndax Pharmaceuticals.
Education
Princeton University (BA in Biology)
Stanford University (MBA)